Form 8-K - Current report:
SEC Accession No. 0001437749-25-015648
Filing Date
2025-05-09
Accepted
2025-05-09 08:57:31
Documents
14
Period of Report
2025-05-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20250507_8k.htm   iXBRL 8-K 23811
  Complete submission text file 0001437749-25-015648.txt   161167

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20250508.xsd EX-101.SCH 3578
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20250508_def.xml EX-101.DEF 11423
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20250508_lab.xml EX-101.LAB 15309
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20250508_pre.xml EX-101.PRE 11583
16 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20250507_8k_htm.xml XML 2857
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 25928563
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)